gsk-1363089 and Wallerian-Degeneration

gsk-1363089 has been researched along with Wallerian-Degeneration* in 1 studies

Other Studies

1 other study(ies) available for gsk-1363089 and Wallerian-Degeneration

ArticleYear
A neuroprotective agent that inactivates prodegenerative TrkA and preserves mitochondria.
    The Journal of cell biology, 2017, 11-06, Volume: 216, Issue:11

    Axon degeneration is an early event and pathological in neurodegenerative conditions and nerve injuries. To discover agents that suppress neuronal death and axonal degeneration, we performed drug screens on primary rodent neurons and identified the pan-kinase inhibitor foretinib, which potently rescued sympathetic, sensory, and motor

    Topics: Adrenergic Fibers; Anilides; Animals; Apoptosis; Apoptosis Regulatory Proteins; Axons; Cells, Cultured; Crush Injuries; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Genotype; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria; Motor Neurons; Mutation; Neurons; Neuroprotective Agents; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Quinolines; Rats, Sprague-Dawley; Receptor, trkA; Sciatic Nerve; Sciatic Neuropathy; Sensory Receptor Cells; Signal Transduction; Superoxide Dismutase-1; Time Factors; Transcription, Genetic; Wallerian Degeneration

2017